Taiwan COVID vaccine maker to apply for EUA after promising Phase II trial results
06/10/2021 05:39 PM
Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Thursday that it would seek an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate after unblinding the results of its Phase II clinical trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Government platform touts 60-80% reduction in statutory animal testing
04/25/2024 10:58 PM - Society
Traffic controls to be enforced at Taipei rallies Saturday
04/25/2024 10:43 PM - Society
High school student injured in earthquake dies
04/25/2024 10:31 PM - Society
Taiwan to remove points system for foreign, overseas compatriot students
04/25/2024 10:06 PM - Culture
Polaroid exhibition showcases work by influential artists, iconic cameras
04/25/2024 09:56 PM